JP2006510654A - 糖尿病を処置する方法 - Google Patents
糖尿病を処置する方法 Download PDFInfo
- Publication number
- JP2006510654A JP2006510654A JP2004558236A JP2004558236A JP2006510654A JP 2006510654 A JP2006510654 A JP 2006510654A JP 2004558236 A JP2004558236 A JP 2004558236A JP 2004558236 A JP2004558236 A JP 2004558236A JP 2006510654 A JP2006510654 A JP 2006510654A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- fluorophenyl
- imidazole
- aryl
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract description 92
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims abstract description 191
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 191
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims abstract description 100
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 91
- 239000008103 glucose Substances 0.000 claims abstract description 90
- 210000004369 blood Anatomy 0.000 claims abstract description 70
- 239000008280 blood Substances 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 38
- 229940122696 MAP kinase inhibitor Drugs 0.000 claims description 72
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 229940043355 kinase inhibitor Drugs 0.000 claims description 12
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 12
- 239000003226 mitogen Substances 0.000 claims description 11
- 230000004580 weight loss Effects 0.000 claims description 8
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 claims description 4
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 claims description 4
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 claims description 4
- 102000056248 Mitogen-activated protein kinase 13 Human genes 0.000 claims description 4
- 102000006303 Chaperonin 60 Human genes 0.000 claims description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 317
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 216
- -1 1-imidazolyl Chemical group 0.000 description 167
- 125000003118 aryl group Chemical group 0.000 description 156
- 125000001072 heteroaryl group Chemical group 0.000 description 127
- 241000699670 Mus sp. Species 0.000 description 105
- 125000000623 heterocyclic group Chemical group 0.000 description 104
- 229910052739 hydrogen Inorganic materials 0.000 description 99
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 98
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 98
- 150000002460 imidazoles Chemical class 0.000 description 97
- 239000001257 hydrogen Substances 0.000 description 93
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 86
- 150000001875 compounds Chemical class 0.000 description 75
- 125000001424 substituent group Chemical group 0.000 description 58
- 239000003981 vehicle Substances 0.000 description 57
- 150000002431 hydrogen Chemical group 0.000 description 55
- 125000005842 heteroatom Chemical group 0.000 description 54
- 229910052760 oxygen Inorganic materials 0.000 description 53
- 229910052717 sulfur Inorganic materials 0.000 description 53
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 51
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 50
- 102000004877 Insulin Human genes 0.000 description 49
- 108090001061 Insulin Proteins 0.000 description 49
- 229940125396 insulin Drugs 0.000 description 49
- 229910052757 nitrogen Inorganic materials 0.000 description 48
- 210000001744 T-lymphocyte Anatomy 0.000 description 46
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 40
- 229910052736 halogen Inorganic materials 0.000 description 37
- 150000002367 halogens Chemical class 0.000 description 37
- 125000000714 pyrimidinyl group Chemical group 0.000 description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 36
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 36
- 230000000694 effects Effects 0.000 description 34
- 125000004093 cyano group Chemical group *C#N 0.000 description 33
- 150000003839 salts Chemical class 0.000 description 33
- 238000011282 treatment Methods 0.000 description 33
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 31
- 125000003710 aryl alkyl group Chemical group 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 125000005843 halogen group Chemical group 0.000 description 30
- 239000003112 inhibitor Substances 0.000 description 30
- 125000003342 alkenyl group Chemical group 0.000 description 28
- 239000003814 drug Substances 0.000 description 28
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 27
- 239000001301 oxygen Substances 0.000 description 27
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 26
- 229910052799 carbon Inorganic materials 0.000 description 26
- 239000000203 mixture Substances 0.000 description 26
- 125000003107 substituted aryl group Chemical group 0.000 description 26
- 239000011593 sulfur Substances 0.000 description 26
- 125000000304 alkynyl group Chemical group 0.000 description 24
- 229940079593 drug Drugs 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 230000003345 hyperglycaemic effect Effects 0.000 description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 21
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 21
- 125000000753 cycloalkyl group Chemical group 0.000 description 20
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 201000001421 hyperglycemia Diseases 0.000 description 19
- 230000008595 infiltration Effects 0.000 description 19
- 238000001764 infiltration Methods 0.000 description 19
- 210000000496 pancreas Anatomy 0.000 description 19
- 239000012826 P38 inhibitor Substances 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 17
- 210000004698 lymphocyte Anatomy 0.000 description 17
- 238000011161 development Methods 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 16
- 125000004122 cyclic group Chemical group 0.000 description 15
- 230000002452 interceptive effect Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 125000000392 cycloalkenyl group Chemical group 0.000 description 14
- 125000004404 heteroalkyl group Chemical group 0.000 description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 13
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000002775 capsule Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- 125000002252 acyl group Chemical group 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 125000002947 alkylene group Chemical group 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 125000003435 aroyl group Chemical group 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 102000043136 MAP kinase family Human genes 0.000 description 10
- 108091054455 MAP kinase family Proteins 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 9
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 210000004153 islets of langerhan Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 8
- 230000003000 nontoxic effect Effects 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 125000002877 alkyl aryl group Chemical group 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000003914 insulin secretion Effects 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 229940126560 MAPK inhibitor Drugs 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- SVSARCCKBMZNMR-UHFFFAOYSA-N [1-[2-[methyl-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethyl]amino]ethyl]pyridin-4-ylidene]methyl-oxoazanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1CCN(C)CCN1C=CC(=C[NH+]=O)C=C1 SVSARCCKBMZNMR-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 125000001589 carboacyl group Chemical group 0.000 description 6
- 230000003915 cell function Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000011888 foil Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000000099 in vitro assay Methods 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 4
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 4
- 108010075254 C-Peptide Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 4
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000002991 immunohistochemical analysis Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 3
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101150031823 HSP70 gene Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 208000007976 Ketosis Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 101150052825 dnaK gene Proteins 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000006371 metabolic abnormality Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 2
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 description 2
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- WVIBCGOMZSLTLD-UHFFFAOYSA-N 4-[5-(2-fluorophenyl)-3-(1-methylpiperidin-4-yl)imidazol-4-yl]-2-methylsulfanylpyrimidine Chemical compound CSC1=NC=CC(C=2N(C=NC=2C=2C(=CC=CC=2)F)C2CCN(C)CC2)=N1 WVIBCGOMZSLTLD-UHFFFAOYSA-N 0.000 description 2
- NGNKFSUSVLQHNU-UHFFFAOYSA-N 4-[5-(2-fluorophenyl)-3-(1-methylpiperidin-4-yl)imidazol-4-yl]-2-methylsulfinylpyrimidine Chemical compound C1CN(C)CCC1N1C(C=2N=C(N=CC=2)S(C)=O)=C(C=2C(=CC=CC=2)F)N=C1 NGNKFSUSVLQHNU-UHFFFAOYSA-N 0.000 description 2
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000021959 Abnormal metabolism Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000002389 essential drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 238000011327 histological measurement Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000012528 insulin ELISA Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 2
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 2
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008263 repair mechanism Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000013389 whole blood assay Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091064702 1 family Proteins 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- XLHUBROMZOAQMV-UHFFFAOYSA-N 1,4-benzosemiquinone Chemical group [O]C1=CC=C(O)C=C1 XLHUBROMZOAQMV-UHFFFAOYSA-N 0.000 description 1
- CIMJBQAYBPMLBL-UHFFFAOYSA-N 1-(2,3-dimethylphenyl)-3-(3-methoxynaphthalen-2-yl)urea Chemical compound COC1=CC2=CC=CC=C2C=C1NC(=O)NC1=CC=CC(C)=C1C CIMJBQAYBPMLBL-UHFFFAOYSA-N 0.000 description 1
- FWYLZUATYISQMP-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-3-[2-methoxy-5-(trifluoromethyl)phenyl]urea Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC1=CC=C(F)C=C1F FWYLZUATYISQMP-UHFFFAOYSA-N 0.000 description 1
- SUCUGGJVKQQPES-UHFFFAOYSA-N 1-(2-fluoro-4-methylphenyl)-3-[2-methoxy-5-(trifluoromethyl)phenyl]urea Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC1=CC=C(C)C=C1F SUCUGGJVKQQPES-UHFFFAOYSA-N 0.000 description 1
- KUGJJKWDMFQOSJ-UHFFFAOYSA-N 1-(2-fluorophenyl)-3-(3-methoxynaphthalen-2-yl)urea Chemical compound COC1=CC2=CC=CC=C2C=C1NC(=O)NC1=CC=CC=C1F KUGJJKWDMFQOSJ-UHFFFAOYSA-N 0.000 description 1
- DWJLOSAVQXZQEK-UHFFFAOYSA-N 1-(3,5-dichloro-4-phenoxyphenyl)-3-[2-methoxy-5-(trifluoromethyl)phenyl]urea Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=CC=CC=C1 DWJLOSAVQXZQEK-UHFFFAOYSA-N 0.000 description 1
- SUEHBAZECVRTOQ-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-3-[2-methoxy-5-(trifluoromethyl)phenyl]urea Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC1=CC=C(F)C(Cl)=C1 SUEHBAZECVRTOQ-UHFFFAOYSA-N 0.000 description 1
- HIXNPJUOIABYJB-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-3-[5-(difluoromethylsulfonyl)-2-methoxyphenyl]urea Chemical compound COC1=CC=C(S(=O)(=O)C(F)F)C=C1NC(=O)NC1=CC=C(F)C(Cl)=C1 HIXNPJUOIABYJB-UHFFFAOYSA-N 0.000 description 1
- ONUBJNPWBUNSDO-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-[2-methoxy-5-(trifluoromethyl)phenyl]urea Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC1=CC=C(C)C(Cl)=C1 ONUBJNPWBUNSDO-UHFFFAOYSA-N 0.000 description 1
- BVGDTMAZIBUCJX-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-[5-(difluoromethylsulfonyl)-2-methoxyphenyl]urea Chemical compound COC1=CC=C(S(=O)(=O)C(F)F)C=C1NC(=O)NC1=CC=C(C)C(Cl)=C1 BVGDTMAZIBUCJX-UHFFFAOYSA-N 0.000 description 1
- RVRRXOGHQFPGEO-UHFFFAOYSA-N 1-(3-fluoro-4-methylphenyl)-3-(3-methoxynaphthalen-2-yl)urea Chemical compound COC1=CC2=CC=CC=C2C=C1NC(=O)NC1=CC=C(C)C(F)=C1 RVRRXOGHQFPGEO-UHFFFAOYSA-N 0.000 description 1
- NACDJICRDYELIJ-UHFFFAOYSA-N 1-(3-fluoro-4-methylphenyl)-3-[2-methoxy-5-(trifluoromethyl)phenyl]urea Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC1=CC=C(C)C(F)=C1 NACDJICRDYELIJ-UHFFFAOYSA-N 0.000 description 1
- CPXWLAHCVVXGEX-UHFFFAOYSA-N 1-(3-fluorophenyl)-3-(3-methoxynaphthalen-2-yl)urea Chemical compound COC1=CC2=CC=CC=C2C=C1NC(=O)NC1=CC=CC(F)=C1 CPXWLAHCVVXGEX-UHFFFAOYSA-N 0.000 description 1
- NARZIXFXYQEUCF-UHFFFAOYSA-N 1-(3-methoxynaphthalen-2-yl)-3-(4-methylphenyl)urea Chemical compound COC1=CC2=CC=CC=C2C=C1NC(=O)NC1=CC=C(C)C=C1 NARZIXFXYQEUCF-UHFFFAOYSA-N 0.000 description 1
- AGSGMXNMNBWVDI-UHFFFAOYSA-N 1-(3-methoxynaphthalen-2-yl)-3-[4-(4-methoxyphenoxy)phenyl]urea Chemical compound C1=CC(OC)=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=CC2=CC=CC=C2C=C1OC AGSGMXNMNBWVDI-UHFFFAOYSA-N 0.000 description 1
- UBZGBQRSXPGADO-UHFFFAOYSA-N 1-(3-methoxynaphthalen-2-yl)-3-[4-(pyridin-4-ylmethyl)phenyl]urea Chemical compound COC1=CC2=CC=CC=C2C=C1NC(=O)NC(C=C1)=CC=C1CC1=CC=NC=C1 UBZGBQRSXPGADO-UHFFFAOYSA-N 0.000 description 1
- RGBHNZLHKCUWSG-UHFFFAOYSA-N 1-(3-methoxynaphthalen-2-yl)-3-naphthalen-1-ylurea Chemical compound C1=CC=C2C(NC(=O)NC3=CC4=CC=CC=C4C=C3OC)=CC=CC2=C1 RGBHNZLHKCUWSG-UHFFFAOYSA-N 0.000 description 1
- JVVLHNHJGIXXCQ-UHFFFAOYSA-N 1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-[4-(pyridin-4-ylmethyl)phenyl]urea Chemical compound OC1=CC([N+]([O-])=O)=C(Cl)C=C1NC(=O)NC(C=C1)=CC=C1CC1=CC=NC=C1 JVVLHNHJGIXXCQ-UHFFFAOYSA-N 0.000 description 1
- ASMCVDDUQQZBFK-UHFFFAOYSA-N 1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea Chemical compound OC1=CC([N+]([O-])=O)=C(Cl)C=C1NC(=O)NC1=CC=CC=C1 ASMCVDDUQQZBFK-UHFFFAOYSA-N 0.000 description 1
- AWNQQYAADTXMNT-UHFFFAOYSA-N 1-(5-tert-butyl-2-methoxyphenyl)-3-(4-phenoxyphenyl)urea Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 AWNQQYAADTXMNT-UHFFFAOYSA-N 0.000 description 1
- KSJWFOMLEIROON-UHFFFAOYSA-N 1-(5-tert-butyl-2-methoxyphenyl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 KSJWFOMLEIROON-UHFFFAOYSA-N 0.000 description 1
- UIIMLVRGKRPKJF-UHFFFAOYSA-N 1-(5-tert-butyl-2-methoxyphenyl)-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1SC1=CC=NC=C1 UIIMLVRGKRPKJF-UHFFFAOYSA-N 0.000 description 1
- OCPGRDMOAPCBAN-UHFFFAOYSA-N 1-(5-tert-butyl-2-methoxyphenyl)-3-[4-(4-methoxyphenoxy)phenyl]urea Chemical compound C1=CC(OC)=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=CC=C1OC OCPGRDMOAPCBAN-UHFFFAOYSA-N 0.000 description 1
- XNIGDEIZAANVJQ-UHFFFAOYSA-N 1-(5-tert-butyl-2-methoxyphenyl)-3-[4-(pyridin-4-ylmethyl)phenyl]urea Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1CC1=CC=NC=C1 XNIGDEIZAANVJQ-UHFFFAOYSA-N 0.000 description 1
- ANGVHJHUUCSQAW-UHFFFAOYSA-N 1-(5-tert-butyl-2-phenylphenyl)-3-(2,3-dichlorophenyl)urea Chemical compound C=1C(C(C)(C)C)=CC=C(C=2C=CC=CC=2)C=1NC(=O)NC1=CC=CC(Cl)=C1Cl ANGVHJHUUCSQAW-UHFFFAOYSA-N 0.000 description 1
- YRHGPXLYOAFTRO-UHFFFAOYSA-N 1-(5-tert-butyl-2-thiophen-3-ylphenyl)-3-(2,3-dichlorophenyl)urea Chemical compound C=1C=CC(Cl)=C(Cl)C=1NC(=O)NC1=CC(C(C)(C)C)=CC=C1C=1C=CSC=1 YRHGPXLYOAFTRO-UHFFFAOYSA-N 0.000 description 1
- XQXIPVQCMSNTRN-UHFFFAOYSA-N 1-[2-methoxy-5-(trifluoromethyl)phenyl]-3-(4-methylphenyl)urea Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC1=CC=C(C)C=C1 XQXIPVQCMSNTRN-UHFFFAOYSA-N 0.000 description 1
- XSIGIAGUVJSXBS-UHFFFAOYSA-N 1-[2-methoxy-5-(trifluoromethyl)phenyl]-3-(4-pyridin-4-ylsulfanylphenyl)urea Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC(C=C1)=CC=C1SC1=CC=NC=C1 XSIGIAGUVJSXBS-UHFFFAOYSA-N 0.000 description 1
- QDWXEIYYKTWRNF-UHFFFAOYSA-N 1-[2-methoxy-5-(trifluoromethyl)phenyl]-3-[4-(pyridin-4-ylmethyl)phenyl]urea Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC(C=C1)=CC=C1CC1=CC=NC=C1 QDWXEIYYKTWRNF-UHFFFAOYSA-N 0.000 description 1
- WYOKSNOAQIXIOE-UHFFFAOYSA-N 1-[2-methoxy-5-(trifluoromethylsulfonyl)phenyl]-3-(4-methylphenyl)urea Chemical compound COC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1NC(=O)NC1=CC=C(C)C=C1 WYOKSNOAQIXIOE-UHFFFAOYSA-N 0.000 description 1
- FUOBTFFYDOUWJF-UHFFFAOYSA-N 1-[5-(difluoromethylsulfonyl)-2-methoxyphenyl]-3-(2,3-dimethylphenyl)urea Chemical compound COC1=CC=C(S(=O)(=O)C(F)F)C=C1NC(=O)NC1=CC=CC(C)=C1C FUOBTFFYDOUWJF-UHFFFAOYSA-N 0.000 description 1
- NSCICEWWQXGDBG-UHFFFAOYSA-N 1-[5-(difluoromethylsulfonyl)-2-methoxyphenyl]-3-(2-fluoro-4-methylphenyl)urea Chemical compound COC1=CC=C(S(=O)(=O)C(F)F)C=C1NC(=O)NC1=CC=C(C)C=C1F NSCICEWWQXGDBG-UHFFFAOYSA-N 0.000 description 1
- ORPATFVSFMGXEK-UHFFFAOYSA-N 1-[5-(difluoromethylsulfonyl)-2-methoxyphenyl]-3-(3-fluoro-4-methylphenyl)urea Chemical compound COC1=CC=C(S(=O)(=O)C(F)F)C=C1NC(=O)NC1=CC=C(C)C(F)=C1 ORPATFVSFMGXEK-UHFFFAOYSA-N 0.000 description 1
- FLQZHESNDLWZGI-UHFFFAOYSA-N 1-[5-(difluoromethylsulfonyl)-2-methoxyphenyl]-3-(4-fluoro-3-methylphenyl)urea Chemical compound COC1=CC=C(S(=O)(=O)C(F)F)C=C1NC(=O)NC1=CC=C(F)C(C)=C1 FLQZHESNDLWZGI-UHFFFAOYSA-N 0.000 description 1
- IQTQAOVHKVVSRJ-UHFFFAOYSA-N 1-[5-(difluoromethylsulfonyl)-2-methoxyphenyl]-3-(4-fluorophenyl)urea Chemical compound COC1=CC=C(S(=O)(=O)C(F)F)C=C1NC(=O)NC1=CC=C(F)C=C1 IQTQAOVHKVVSRJ-UHFFFAOYSA-N 0.000 description 1
- JNGWTTDGSWDQFT-UHFFFAOYSA-N 1-[5-(difluoromethylsulfonyl)-2-methoxyphenyl]-3-(4-methylphenyl)urea Chemical compound COC1=CC=C(S(=O)(=O)C(F)F)C=C1NC(=O)NC1=CC=C(C)C=C1 JNGWTTDGSWDQFT-UHFFFAOYSA-N 0.000 description 1
- AUWOOQSOMNALEH-UHFFFAOYSA-N 1-[5-tert-butyl-2-(oxolan-3-yloxy)phenyl]-3-(2,3-dichlorophenyl)urea Chemical compound C=1C=CC(Cl)=C(Cl)C=1NC(=O)NC1=CC(C(C)(C)C)=CC=C1OC1CCOC1 AUWOOQSOMNALEH-UHFFFAOYSA-N 0.000 description 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- AKMVOBFZFANXPT-UHFFFAOYSA-N 2-(3-fluorophenoxy)-4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]pyrimidine Chemical compound C1=CC(F)=CC=C1C1=C(C=2N=C(OC=3C=C(F)C=CC=3)N=CC=2)N(C2CCNCC2)C=N1 AKMVOBFZFANXPT-UHFFFAOYSA-N 0.000 description 1
- BWDVVDQAECUHAD-UHFFFAOYSA-N 2-[4-(4-fluorophenyl)-5-pyridin-4-ylimidazol-1-yl]acetaldehyde Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CC=O)C=N1 BWDVVDQAECUHAD-UHFFFAOYSA-N 0.000 description 1
- CIFYBLVHQQNVPW-UHFFFAOYSA-N 2-[4-(4-fluorophenyl)-5-pyridin-4-ylimidazol-1-yl]acetonitrile Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CC#N)C=N1 CIFYBLVHQQNVPW-UHFFFAOYSA-N 0.000 description 1
- ZFXKBQLAXHAGGU-UHFFFAOYSA-N 2-[4-tert-butyl-2-(naphthalen-1-ylcarbamoylamino)phenoxy]-n-methylacetamide Chemical compound CNC(=O)COC1=CC=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC2=CC=CC=C12 ZFXKBQLAXHAGGU-UHFFFAOYSA-N 0.000 description 1
- NQSGLPJENUWZCH-UHFFFAOYSA-N 2-[4-tert-butyl-2-[(2,3-dichlorophenyl)carbamoylamino]phenoxy]-n-methylacetamide Chemical compound CNC(=O)COC1=CC=C(C(C)(C)C)C=C1NC(=O)NC1=CC=CC(Cl)=C1Cl NQSGLPJENUWZCH-UHFFFAOYSA-N 0.000 description 1
- OJBGEOXGUGYQKZ-UHFFFAOYSA-N 2-[[4-(4-fluorophenyl)-4-[1-(1-methylpiperidin-4-yl)imidazol-2-yl]-1h-pyrimidin-5-yl]amino]ethanol Chemical compound C1CN(C)CCC1N1C(C2(C(=CN=CN2)NCCO)C=2C=CC(F)=CC=2)=NC=C1 OJBGEOXGUGYQKZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- AIZGSJRXZMRUPZ-UHFFFAOYSA-N 3-[4-(4-fluorophenyl)-5-pyridin-4-ylimidazol-1-yl]propan-1-amine Chemical compound NCCCN1C=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 AIZGSJRXZMRUPZ-UHFFFAOYSA-N 0.000 description 1
- RTMLHKIXCXINOY-UHFFFAOYSA-N 3-[4-[[2-methoxy-5-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(OC=2C=CC(NC(=O)NC=3C(=CC=C(C=3)C(F)(F)F)OC)=CC=2)=C1 RTMLHKIXCXINOY-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- NSJCXUONRHOYTD-UHFFFAOYSA-N 4-(3-methyl-5-phenylimidazol-4-yl)pyridine Chemical compound CN1C=NC(C=2C=CC=CC=2)=C1C1=CC=NC=C1 NSJCXUONRHOYTD-UHFFFAOYSA-N 0.000 description 1
- ROKOFZNQCIIJMI-UHFFFAOYSA-N 4-(4-fluorophenyl)-1-cycloropropylmethyl-5-(4-pyridyl)-imidazole Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CC2CC2)C=N1 ROKOFZNQCIIJMI-UHFFFAOYSA-N 0.000 description 1
- DFEYXQGDDCDXJK-UHFFFAOYSA-N 4-(fluorophenyl)-1-cyclopropylmethyl-5-(2-amino-4-pyrimidinyl)imidazole Chemical compound NC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)CC2CC2)=N1 DFEYXQGDDCDXJK-UHFFFAOYSA-N 0.000 description 1
- AIOGIOXZTSANRS-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazol-3-yl]pyridine Chemical compound C1=CC(SC)=CC=C1C1=NN(C=2C=CC(F)=CC=2)C(C=2C=CN=CC=2)=C1 AIOGIOXZTSANRS-UHFFFAOYSA-N 0.000 description 1
- AHTLNQTUFYXPRA-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-5-phenyl-1,2,4-triazol-3-yl]pyrimidin-2-amine Chemical compound NC1=NC=CC(C=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(F)=CC=2)=N1 AHTLNQTUFYXPRA-UHFFFAOYSA-N 0.000 description 1
- SWIJDEXXOUYONJ-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-5-phenyl-3,4-dihydropyrazol-3-yl]pyridine Chemical compound C1=CC(F)=CC=C1N1C(C=2C=CN=CC=2)CC(C=2C=CC=CC=2)=N1 SWIJDEXXOUYONJ-UHFFFAOYSA-N 0.000 description 1
- HLGKABKRPQXWAD-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-5-phenylpyrazol-3-yl]pyridine Chemical compound C1=CC(F)=CC=C1N1C(C=2C=CN=CC=2)=CC(C=2C=CC=CC=2)=N1 HLGKABKRPQXWAD-UHFFFAOYSA-N 0.000 description 1
- AYKRXRVXSJGBJP-UHFFFAOYSA-N 4-[2-[4-(4-fluorophenyl)-5-pyridin-4-ylimidazol-1-yl]ethyl]morpholine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CCN2CCOCC2)C=N1 AYKRXRVXSJGBJP-UHFFFAOYSA-N 0.000 description 1
- HWDWUCGVKZNRLM-UHFFFAOYSA-N 4-[3-(1-benzylpiperidin-4-yl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(C2CCN(CC=3C=CC=CC=3)CC2)C=N1 HWDWUCGVKZNRLM-UHFFFAOYSA-N 0.000 description 1
- XGMKXFYSDRBOQV-UHFFFAOYSA-N 4-[3-(1-benzylpiperidin-4-yl)-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine Chemical compound NC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCN(CC=3C=CC=CC=3)CC2)=N1 XGMKXFYSDRBOQV-UHFFFAOYSA-N 0.000 description 1
- CQKBAFMCHSKLIS-UHFFFAOYSA-N 4-[3-(2,2-diethoxyethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine Chemical compound CCOC(OCC)CN1C=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 CQKBAFMCHSKLIS-UHFFFAOYSA-N 0.000 description 1
- IYFMAQVLNAMSDV-UHFFFAOYSA-N 4-[3-(3-azidopropyl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CCCN=[N+]=[N-])C=N1 IYFMAQVLNAMSDV-UHFFFAOYSA-N 0.000 description 1
- ASURDJICBXIBQJ-UHFFFAOYSA-N 4-[3-(3-chloropropyl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CCCCl)C=N1 ASURDJICBXIBQJ-UHFFFAOYSA-N 0.000 description 1
- SFXOARXWTVMVAK-UHFFFAOYSA-N 4-[3-(4-fluorophenyl)-5-phenyl-1,2,4-triazol-4-yl]pyrimidin-2-amine Chemical compound NC1=NC=CC(N2C(=NN=C2C=2C=CC=CC=2)C=2C=CC(F)=CC=2)=N1 SFXOARXWTVMVAK-UHFFFAOYSA-N 0.000 description 1
- MFWRRYPZURQIQM-UHFFFAOYSA-N 4-[3-[4-(3-methylsulfanylphenyl)-5-pyridin-4-ylimidazol-1-yl]propyl]morpholine Chemical compound CSC1=CC=CC(C2=C(N(CCCN3CCOCC3)C=N2)C=2C=CN=CC=2)=C1 MFWRRYPZURQIQM-UHFFFAOYSA-N 0.000 description 1
- KCUQHXZKXUPMGH-UHFFFAOYSA-N 4-[3-[4-(4-fluorophenyl)-5-(2-methylpyridin-4-yl)imidazol-1-yl]propyl]morpholine Chemical compound C1=NC(C)=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)CCCN2CCOCC2)=C1 KCUQHXZKXUPMGH-UHFFFAOYSA-N 0.000 description 1
- VSGGNWLHIXUIFA-UHFFFAOYSA-N 4-[3-[4-(4-fluorophenyl)-5-(2-methylsulfanylpyrimidin-4-yl)imidazol-1-yl]propyl]morpholine Chemical compound CSC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)CCCN2CCOCC2)=N1 VSGGNWLHIXUIFA-UHFFFAOYSA-N 0.000 description 1
- ANWALZPQHPAZFO-UHFFFAOYSA-N 4-[3-[4-(4-fluorophenyl)-5-pyridin-4-ylimidazol-1-yl]propyl]morpholine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CCCN2CCOCC2)C=N1 ANWALZPQHPAZFO-UHFFFAOYSA-N 0.000 description 1
- FMYFBNBXSCWATQ-UHFFFAOYSA-N 4-[3-[4-(4-fluorophenyl)-5-quinolin-4-ylimidazol-1-yl]propyl]morpholine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C3=CC=CC=C3N=CC=2)N(CCCN2CCOCC2)C=N1 FMYFBNBXSCWATQ-UHFFFAOYSA-N 0.000 description 1
- AYAROVRXASJFBJ-UHFFFAOYSA-N 4-[3-[5-(2-chloropyridin-4-yl)-4-(4-fluorophenyl)imidazol-1-yl]propyl]morpholine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=C(Cl)N=CC=2)N(CCCN2CCOCC2)C=N1 AYAROVRXASJFBJ-UHFFFAOYSA-N 0.000 description 1
- VXSHGJJXHHEQII-UHFFFAOYSA-N 4-[3-cyclopropyl-5-(4-fluorophenyl)imidazol-4-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(C2CC2)C=N1 VXSHGJJXHHEQII-UHFFFAOYSA-N 0.000 description 1
- XCBMRVUKLWKIKB-UHFFFAOYSA-N 4-[3-methyl-5-(3-methylsulfanylphenyl)imidazol-4-yl]pyridine Chemical compound CSC1=CC=CC(C2=C(N(C)C=N2)C=2C=CN=CC=2)=C1 XCBMRVUKLWKIKB-UHFFFAOYSA-N 0.000 description 1
- GCYKARFOKUYUKZ-UHFFFAOYSA-N 4-[3-tert-butyl-5-(4-fluorophenyl)imidazol-4-yl]pyridine Chemical compound CC(C)(C)N1C=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 GCYKARFOKUYUKZ-UHFFFAOYSA-N 0.000 description 1
- CXHQVXVSPTVPGL-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-methylsulfanylphenyl)-1h-imidazol-5-yl]-2-methoxypyrimidine Chemical compound COC1=NC=CC(C2=C(N=C(N2)C=2C=CC(SC)=CC=2)C=2C=CC(F)=CC=2)=N1 CXHQVXVSPTVPGL-UHFFFAOYSA-N 0.000 description 1
- PGIHJRODUCFJJR-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-methylsulfanylphenyl)-1h-imidazol-5-yl]-2-phenoxypyrimidine Chemical compound C1=CC(SC)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2N=C(OC=3C=CC=CC=3)N=CC=2)N1 PGIHJRODUCFJJR-UHFFFAOYSA-N 0.000 description 1
- GXSMKOXIBHMNPW-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1h-imidazol-5-yl]-2-methoxypyrimidine Chemical compound COC1=NC=CC(C2=C(N=C(N2)C=2C=CC(=CC=2)S(C)=O)C=2C=CC(F)=CC=2)=N1 GXSMKOXIBHMNPW-UHFFFAOYSA-N 0.000 description 1
- ZQUSFAUAYSEREK-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1-imidazolyl]-1-cyclohexanol Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCC(O)CC2)=N1 ZQUSFAUAYSEREK-UHFFFAOYSA-N 0.000 description 1
- SIXQRWZCONFXSS-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-one Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCC(=O)CC2)=N1 SIXQRWZCONFXSS-UHFFFAOYSA-N 0.000 description 1
- QCAKPSJBLVXPSQ-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-5-pyridin-4-ylimidazol-1-yl]piperidine-1-carbaldehyde Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(C2CCN(CC2)C=O)C=N1 QCAKPSJBLVXPSQ-UHFFFAOYSA-N 0.000 description 1
- GLPPXWMKYPZQJS-UHFFFAOYSA-N 4-[4-[4-(4-fluorophenyl)-5-pyridin-4-ylimidazol-1-yl]butyl]morpholine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CCCCN2CCOCC2)C=N1 GLPPXWMKYPZQJS-UHFFFAOYSA-N 0.000 description 1
- DNHOUTJKIADFQO-UHFFFAOYSA-N 4-[4-bromo-2-(4-fluorophenyl)-5-phenylpyrazol-3-yl]pyridine Chemical compound C1=CC(F)=CC=C1N1C(C=2C=CN=CC=2)=C(Br)C(C=2C=CC=CC=2)=N1 DNHOUTJKIADFQO-UHFFFAOYSA-N 0.000 description 1
- LAXPDWNGVMRQAT-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(1-methylpiperidin-4-yl)imidazol-4-yl]-n-(3-morpholin-4-ylpropyl)pyrimidin-2-amine Chemical compound C1CN(C)CCC1N1C(C=2N=C(NCCCN3CCOCC3)N=CC=2)=C(C=2C=CC(F)=CC=2)N=C1 LAXPDWNGVMRQAT-UHFFFAOYSA-N 0.000 description 1
- LKIOISBDXPXOKL-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(1-methylpiperidin-4-yl)imidazol-4-yl]-n-(thian-4-yl)pyrimidin-2-amine Chemical compound C1CN(C)CCC1N1C(C=2N=C(NC3CCSCC3)N=CC=2)=C(C=2C=CC(F)=CC=2)N=C1 LKIOISBDXPXOKL-UHFFFAOYSA-N 0.000 description 1
- YYDDMXDPAQDGME-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(1-methylpiperidin-4-yl)imidazol-4-yl]-n-propan-2-ylpyrimidin-2-amine Chemical compound CC(C)NC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCN(C)CC2)=N1 YYDDMXDPAQDGME-UHFFFAOYSA-N 0.000 description 1
- NJBOQGZRBOSMCW-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(2-methylsulfanylphenyl)imidazol-4-yl]pyridine Chemical compound CSC1=CC=CC=C1N1C(C=2C=CN=CC=2)=C(C=2C=CC(F)=CC=2)N=C1 NJBOQGZRBOSMCW-UHFFFAOYSA-N 0.000 description 1
- WHXPUOMLBIINHX-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(2-methylsulfinylphenyl)imidazol-4-yl]pyridine Chemical compound CS(=O)C1=CC=CC=C1N1C(C=2C=CN=CC=2)=C(C=2C=CC(F)=CC=2)N=C1 WHXPUOMLBIINHX-UHFFFAOYSA-N 0.000 description 1
- KCRPPQYLFPCZML-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(3-methylsulfanylphenyl)imidazol-4-yl]pyridine Chemical compound CSC1=CC=CC(N2C(=C(N=C2)C=2C=CC(F)=CC=2)C=2C=CN=CC=2)=C1 KCRPPQYLFPCZML-UHFFFAOYSA-N 0.000 description 1
- PLUFSXPPGWXWEZ-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(3-methylsulfanylpropyl)imidazol-4-yl]pyridine Chemical compound CSCCCN1C=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 PLUFSXPPGWXWEZ-UHFFFAOYSA-N 0.000 description 1
- JUSVEWRLNMHNJO-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(3-methylsulfonylpropyl)imidazol-4-yl]pyridine Chemical compound CS(=O)(=O)CCCN1C=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 JUSVEWRLNMHNJO-UHFFFAOYSA-N 0.000 description 1
- RAVFPWNPAGEFFU-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(3-morpholin-4-ylpropyl)imidazol-4-yl]pyridin-2-amine Chemical compound C1=NC(N)=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)CCCN2CCOCC2)=C1 RAVFPWNPAGEFFU-UHFFFAOYSA-N 0.000 description 1
- JDDSPCRIJZRHBB-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(3-morpholin-4-ylpropyl)imidazol-4-yl]pyrimidin-2-amine Chemical compound NC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)CCCN2CCOCC2)=N1 JDDSPCRIJZRHBB-UHFFFAOYSA-N 0.000 description 1
- PGUXJVJYJAXTTL-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(3-phenoxypropyl)imidazol-4-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CCCOC=2C=CC=CC=2)C=N1 PGUXJVJYJAXTTL-UHFFFAOYSA-N 0.000 description 1
- HSIJDSUYWFNDTO-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(3-phenylsulfanylpropyl)imidazol-4-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CCCSC=2C=CC=CC=2)C=N1 HSIJDSUYWFNDTO-UHFFFAOYSA-N 0.000 description 1
- VXPXIUXUARYSEH-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(3-piperidin-1-ylpropyl)imidazol-4-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CCCN2CCCCC2)C=N1 VXPXIUXUARYSEH-UHFFFAOYSA-N 0.000 description 1
- XYBYJNUTYQCHIH-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(3-pyrrolidin-1-ylpropyl)imidazol-4-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N(CCCN2CCCC2)C=N1 XYBYJNUTYQCHIH-UHFFFAOYSA-N 0.000 description 1
- LKVCIGKNYDMCEB-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(4-methylsulfanylphenyl)imidazol-4-yl]pyridine Chemical compound C1=CC(SC)=CC=C1N1C(C=2C=CN=CC=2)=C(C=2C=CC(F)=CC=2)N=C1 LKVCIGKNYDMCEB-UHFFFAOYSA-N 0.000 description 1
- UPYYEIHAZSVKFD-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-(4-methylsulfinylphenyl)imidazol-4-yl]pyridine Chemical compound C1=CC(S(=O)C)=CC=C1N1C(C=2C=CN=CC=2)=C(C=2C=CC(F)=CC=2)N=C1 UPYYEIHAZSVKFD-UHFFFAOYSA-N 0.000 description 1
- RJNISNTYBZDCSB-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-phenyl-1,2,4-triazol-1-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=NC(C=2C=CC=CC=2)=NN1C1=CC=NC=C1 RJNISNTYBZDCSB-UHFFFAOYSA-N 0.000 description 1
- ZXAWHDKYRBFPMS-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-propan-2-ylimidazol-4-yl]pyridine Chemical compound CC(C)N1C=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 ZXAWHDKYRBFPMS-UHFFFAOYSA-N 0.000 description 1
- XVCSWAQWAKYULT-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-propan-2-ylimidazol-4-yl]pyrimidin-2-amine Chemical compound CC(C)N1C=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC(N)=N1 XVCSWAQWAKYULT-UHFFFAOYSA-N 0.000 description 1
- DLGZLIXYVSQGOX-UHFFFAOYSA-N 4-[8-[4-(4-tert-butylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxamide Chemical compound C1CN(C(C)(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=COC(C(N)=O)=C1 DLGZLIXYVSQGOX-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 125000004864 4-thiomethylphenyl group Chemical group 0.000 description 1
- FYMQPWWNOCENRN-UHFFFAOYSA-N 6,7-dimethoxyquinazoline Chemical compound N1=CN=C2C=C(OC)C(OC)=CC2=C1 FYMQPWWNOCENRN-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- VSRHGFRXBAPGJT-UHFFFAOYSA-N 6-[5-(4-fluorophenyl)-3-phenyl-1,2,4-triazol-1-yl]pyrimidin-4-amine Chemical compound C1=NC(N)=CC(N2C(=NC(=N2)C=2C=CC=CC=2)C=2C=CC(F)=CC=2)=N1 VSRHGFRXBAPGJT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- BZJMOMZWBLPXPX-UHFFFAOYSA-N FC1=CC=C(C=C1)C=1N(C=CN=1)C1CCN(CC1)C(C)C(=O)O Chemical compound FC1=CC=C(C=C1)C=1N(C=CN=1)C1CCN(CC1)C(C)C(=O)O BZJMOMZWBLPXPX-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101001036709 Homo sapiens Heat shock protein beta-1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 101100438957 Mus musculus Cd8a gene Proteins 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- VSPFURGQAYMVAN-UHFFFAOYSA-N SB220025 Chemical compound NC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCNCC2)=N1 VSPFURGQAYMVAN-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- WRWYGOVGIGCDLE-UHFFFAOYSA-N [O]c1ccccc1F Chemical group [O]c1ccccc1F WRWYGOVGIGCDLE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical group O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- WOBGSBYWOWXDST-UHFFFAOYSA-N n-(3-bromophenyl)-4-[5-(4-fluorophenyl)-3-(1-methylpiperidin-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCC1N1C(C=2N=C(NC=3C=C(Br)C=CC=3)N=CC=2)=C(C=2C=CC(F)=CC=2)N=C1 WOBGSBYWOWXDST-UHFFFAOYSA-N 0.000 description 1
- JWIZNWSRZFIMGA-UHFFFAOYSA-N n-[3-[4-(4-fluorophenyl)-5-pyridin-4-ylimidazol-1-yl]propyl]methanesulfonamide Chemical compound CS(=O)(=O)NCCCN1C=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 JWIZNWSRZFIMGA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GUQRKZPMVLRXLT-UHFFFAOYSA-N n-cyclohexylhydroxylamine Chemical compound ONC1CCCCC1 GUQRKZPMVLRXLT-UHFFFAOYSA-N 0.000 description 1
- CXEXTPDLKDYOMC-UHFFFAOYSA-N n-ethyl-4-[5-(4-fluorophenyl)-3-(1-methylpiperidin-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound CCNC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCN(C)CC2)=N1 CXEXTPDLKDYOMC-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- JVJQPDTXIALXOG-UHFFFAOYSA-N nitryl fluoride Chemical compound [O-][N+](F)=O JVJQPDTXIALXOG-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical group C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- SZZUIQWBYMKKDO-RJNTXXOISA-M potassium;(2e,4e)-hexa-2,4-dienoate;(2e,4e)-hexa-2,4-dienoic acid Chemical compound [K+].C\C=C\C=C\C(O)=O.C\C=C\C=C\C([O-])=O SZZUIQWBYMKKDO-RJNTXXOISA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43124102P | 2002-12-06 | 2002-12-06 | |
| PCT/US2003/040140 WO2004053107A2 (en) | 2002-12-06 | 2003-12-05 | Methods for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510654A true JP2006510654A (ja) | 2006-03-30 |
| JP2006510654A5 JP2006510654A5 (enExample) | 2007-02-01 |
Family
ID=32507688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004558236A Pending JP2006510654A (ja) | 2002-12-06 | 2003-12-05 | 糖尿病を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040171659A1 (enExample) |
| EP (1) | EP1583535A4 (enExample) |
| JP (1) | JP2006510654A (enExample) |
| AU (1) | AU2003299652A1 (enExample) |
| CA (1) | CA2511763A1 (enExample) |
| WO (1) | WO2004053107A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7765004B2 (en) * | 2005-04-28 | 2010-07-27 | Cardiac Pacemakers, Inc. | Methods and systems for managing fusion and noise in cardiac pacing response classification |
| WO2007075896A2 (en) * | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| CA2857374A1 (en) * | 2011-09-02 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | Camkii, ip3r, calcineurin, p38 and mk2/3 inhibitors to treat metabolic disturbances of obesity |
| PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4619652A (en) * | 1982-12-23 | 1986-10-28 | Alza Corporation | Dosage form for use in a body mounted pump |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JP2000506532A (ja) * | 1996-03-13 | 2000-05-30 | スミスクライン・ビーチャム・コーポレイション | サイトカイン介在疾患の治療にて有用な新規ピリミジン化合物 |
| GB9713726D0 (en) * | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| PL340412A1 (en) * | 1997-10-20 | 2001-01-29 | Hoffmann La Roche | Bicyclic kinase inhibitors |
| US6589954B1 (en) * | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| US6599710B1 (en) * | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| AU772295B2 (en) * | 1999-05-21 | 2004-04-22 | Scios Inc. | Indole-type derivatives as inhibitors of p38 kinase |
-
2003
- 2003-12-05 EP EP03799936A patent/EP1583535A4/en not_active Withdrawn
- 2003-12-05 AU AU2003299652A patent/AU2003299652A1/en not_active Abandoned
- 2003-12-05 CA CA002511763A patent/CA2511763A1/en not_active Abandoned
- 2003-12-05 JP JP2004558236A patent/JP2006510654A/ja active Pending
- 2003-12-05 US US10/728,665 patent/US20040171659A1/en not_active Abandoned
- 2003-12-05 WO PCT/US2003/040140 patent/WO2004053107A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004053107A2 (en) | 2004-06-24 |
| CA2511763A1 (en) | 2004-06-24 |
| EP1583535A4 (en) | 2008-03-19 |
| US20040171659A1 (en) | 2004-09-02 |
| EP1583535A2 (en) | 2005-10-12 |
| AU2003299652A8 (en) | 2004-06-30 |
| WO2004053107A3 (en) | 2004-10-07 |
| AU2003299652A1 (en) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6995822B2 (ja) | Ｄｐｐ ｉｖインヒビターの使用 | |
| KR102062824B1 (ko) | 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도 | |
| Toyoshima et al. | Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes | |
| US8058264B2 (en) | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | |
| US8853277B2 (en) | Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC) | |
| Mu et al. | Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice | |
| US20030186977A1 (en) | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy | |
| US20140187595A1 (en) | Methods and Compositions Comprising AMPK Activator (Metformin/Troglitazone) for the Treatment of Myotonic Dystrophy Type 1 (DM1) | |
| US20070254863A1 (en) | Use of CBx cannabinoid receptor modulators as potassium channel modulators | |
| Massella et al. | Cyclosporine A treatment in patients with Alport syndrome: a single-center experience | |
| JP2006512369A (ja) | ＴＧＦ−β阻害剤を用いる肥満症および関連症状の処置 | |
| US20170216250A1 (en) | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor | |
| TW200803896A (en) | Method of improvement of cognitive function | |
| EP3493794A1 (en) | Use of swell1 inhibitors and modulators to treat type 2 diabetes and obesity | |
| SK12312003A3 (sk) | Použitie N-fenyl-2-pyridínamínových derivátov proti ochoreniam s účasťou žírnych buniek | |
| CA2471566A1 (en) | Combination of mtp inhibitors or apob-secretion inhibitors with fibrates for use as pharmaceuticals | |
| DeMarco et al. | Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2) 27 rat | |
| Park et al. | YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model | |
| JP2006510654A (ja) | 糖尿病を処置する方法 | |
| US5021448A (en) | Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist | |
| WO2011032099A1 (en) | Methods of treating diastolic dysfunction and related conditions | |
| US20070191357A1 (en) | Methods of using potassium channel inhibiting compounds | |
| Santoro et al. | An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease | |
| JP2006508051A (ja) | 骨形成を促進する方法 | |
| US20030162788A1 (en) | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061204 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061204 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080419 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100302 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100727 |